Using tumor antigen-loaded monocyte-derived DCs for therapeutic vaccination is a strategy that has been well explored, but with mixed clinical results. While this strategy can be effective, it is limited by the requirement for accessible tumor...Read More
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
One of the reasons immune checkpoint blockade (ICB) may fail in solid tumors like pancreatic ductal adenocarcinoma (PDA) is a lack of T cell infiltration and extensive myeloid inflammation in the tumor microenvironment (TME). Wattenberg et al. aimed to...
Dendritic cell (DC)-based cancer vaccines have great potential but are currently lacking in efficacy. Adamik et al. investigated the transcriptomic and immune-metabolic characteristics of DCs from patients with melanoma to better understand how cancer may impact antigen presentation function...
This week’s extensive special feature covers select talks from the SITC - 38th Annual Meeting 2023 in San Diego, CA. We have organized the content by topics below. Keynote AddressSusan Kaech Microbiome and metabolismSusan BullmanYoungseok ChoLydia Lynch Cell-based immunotherapiesFelix...
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Katherine J. Turner
Samuel (Sandy) Goldman
Elaine Yee Lin Chung
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
In less than a minute, link your credit card with our partner RoundUp App.
Every purchase you make with that card will be rounded up and the change will be donated to ACIR.
All transactions are securely made through Stripe.